Oracle stock price jumps 3% as ORCL outpaces tech in morning trade
26 January 2026
1 min read

Oracle stock price jumps 3% as ORCL outpaces tech in morning trade

New York, Jan 26, 2026, 10:49 EST — Regular session

  • Oracle shares climbed roughly 3.3%, outpacing the broader tech sector’s gains.
  • A fresh life-sciences client has started using the company’s Argus safety software, the firm revealed.
  • Traders are focused on the Fed’s rate decision set for Jan. 28 and Oracle’s earnings due in mid-March.

Oracle shares climbed 3.3% to $182.98 on Monday, beating the tech sector’s 0.7% increase and the Nasdaq 100’s roughly 0.5% gain. Microsoft and Amazon also pushed higher.

This shift is significant as Oracle has weighed heavily in the debate over how quickly heavy AI infrastructure spending translates into revenue. Back in December, the stock dropped after the company’s forecasts came up short and it warned of much higher capital expenditures. 1

Investors are gearing up for the Federal Reserve meeting this week, which could shift rate expectations and impact risk appetite in mega-cap tech. The Fed convenes January 27-28, with its decision set for Wednesday. 2

Oracle highlighted new customer interest in a specialized area of its software lineup. Voisin Consulting Life Sciences, a contract research organization, selected Oracle Argus for pharmacovigilance tasks, the company announced. Seema Verma, Oracle Health and Life Sciences executive vice president, described it as a “dependable, advanced safety solution.” 3

This announcement veers away from the cloud-infrastructure story that’s fueled Oracle’s ups and downs. Still, it bolsters management’s argument that the company can push vertical software alongside its platform services.

Oracle has pointed to contracted cloud commitments to signal demand strength. In its fiscal second-quarter results released in December, the company reported $523 billion in remaining performance obligations—a metric showing contracted revenue still to be recognized—and noted a 68% jump in cloud infrastructure revenue. 4

The sticking point remains how those commitments will actually be fulfilled. Oracle’s expansion has drawn sharp questions about financing and follow-through, especially after bondholders sued over disclosures related to debt for AI infrastructure. 5

Another risk: changes in rates or credit conditions might hit highly capital-intensive trade setups first, even if the core demand remains steady.

Traders are now focused on whether Monday’s shift will stick after the Fed’s Jan. 28 decision, a key date that could shake up rate-sensitive tech stocks.

Oracle plans to release its fiscal third-quarter update in mid-March, according to the company. 6

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Northern Dynasty (NAK) stock jumps 16% as gold hits $5,100 and Pebble case deadline nears
Previous Story

Northern Dynasty (NAK) stock jumps 16% as gold hits $5,100 and Pebble case deadline nears

Palantir stock price today: PLTR slips as Fed week starts and Feb. 2 earnings loom
Next Story

Palantir stock price today: PLTR slips as Fed week starts and Feb. 2 earnings loom

Go toTop